Join us for our upcoming webinar, “Navigating Desmoid Tumor Treatment Options & Insights on Zolucatetide (FOG-001)” with Dr. Gregory Cote, DTRF Medical Advisory Board Member and medical oncologist at Mass General Brigham Cancer Institute to explore current treatment options for people living with desmoid tumors.

This session will include a high-level overview of today’s treatment landscape, including gamma secretase inhibitor therapies (GSIs), sorafenib, chemotherapy and non-drug treatment options, as well as emerging clinical trials. Dr. Cote will share early updates on zolucatetide (formerly known as FOG-001), including how it works within the Wnt/β-catenin pathway and how it differs from other available treatments. Together, we’ll walk through what is currently known about the trial, including how the study is structured, early signals of effectiveness, and what patients should understand about potential side effects and tradeoffs.

The discussion will also highlight how patients and their care teams can approach decision-making around experimental therapies, balancing potential benefits, risks, and access considerations. This webinar is designed to help patients and caregivers better understand their options and feel more informed when discussing treatment decisions with their medical team.

We’ll reserve dedicated time for an in-depth Q&A, giving you the opportunity to ask Dr. Cote your questions and hear directly from a leading expert.

Register today!